According to Zacks, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. “
Other equities research analysts also recently issued reports about the company. ValuEngine downgraded Retrophin from a “strong-buy” rating to a “buy” rating in a report on Friday, April 17th. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a report on Saturday. BTIG Research started coverage on Retrophin in a report on Tuesday, June 16th. They issued a “buy” rating and a $25.00 price target for the company. Canaccord Genuity reiterated a “buy” rating and issued a $26.00 price target on shares of Retrophin in a report on Tuesday, May 19th. Finally, BMO Capital Markets boosted their price target on Retrophin from $33.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, May 12th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Retrophin currently has an average rating of “Buy” and a consensus target price of $26.50.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.70. Retrophin had a negative return on equity of 43.15% and a negative net margin of 57.01%. The company had revenue of $47.77 million for the quarter, compared to the consensus estimate of $43.14 million. As a group, sell-side analysts anticipate that Retrophin will post -1.56 EPS for the current year.
In other Retrophin news, Director Steve Aselage sold 3,062 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $15.09, for a total transaction of $46,205.58. Following the completion of the transaction, the director now owns 252,857 shares in the company, valued at approximately $3,815,612.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 16,364 shares of company stock valued at $298,850 in the last quarter. 4.63% of the stock is currently owned by insiders.
A number of hedge funds have recently made changes to their positions in RTRX. Nisa Investment Advisors LLC raised its stake in shares of Retrophin by 103.1% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,970 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,000 shares in the last quarter. Great West Life Assurance Co. Can bought a new stake in shares of Retrophin in the 4th quarter worth $50,000. SG Americas Securities LLC acquired a new stake in shares of Retrophin during the first quarter worth $122,000. Calton & Associates Inc. acquired a new stake in shares of Retrophin during the first quarter worth $158,000. Finally, Caxton Associates LP acquired a new stake in shares of Retrophin during the fourth quarter worth $161,000.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Further Reading: Commodities
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.